Press Releases

Press Releases

View allRegulatory

  • Interim Report 1 October to 31 December 2020

    February 12, 2021 08:31 (CET)
    Regulatory
    MAR

    Financial Summary for the group

    Read more

  • Cyxone's presentation at Aktiedagen 27 January now published

    January 28, 2021 09:12 (CET)

    Cyxone’s CEO Tara Heitner presented the company at Aktiespararnas Aktiedagen on 27 January 2021. Click here to see the video (https://youtu.be/9PgXRnk-nRo).

    Read more

  • Cyxone presents at Aktiedagen the 27 January 2021

    January 20, 2021 09:20 (CET)

    CEO Tara Heitner will present the latest updates in Cyxone on 27 January at 20.30 at the online event Aktiedagen. Information about the event together with the agenda is found on the event’s webpage (https://www.aktiespararna.se/aktiviteter/aktiedagen-lund-digitalt). Follow the presentation live here (https://www.aktiespararna.se/tv/live).

    Read more

  • Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod

    January 15, 2021 13:05 (CET)
    Regulatory

    Cyxone (publ.) announced today that the first patient has been screened in the Phase 2 clinical trial of Rabeximod in Covid-19. The trial will evaluate the efficacy and safety of oral treatment with Rabeximod to prevent disease progression in hospitalized Covid-19 patients and shorten the time to recovery. The study will include 300 patients at clinical centers in Poland, Slovakia and up to three additional countries in Europe. Cyxone expects to announce preliminary results in the third quarter of 2021.

    Read more

  • First Berlin Equity Research publishes independent analysis of Cyxone

    December 17, 2020 16:16 (CET)

    Cyxone (publ.), a clinical stage biotech company developing first-in-class drugs for diseases of the immune system, announces today that the research company First Berlin Equity Research has published an independent analysis report of Cyxone.

    Read more

  • Cyxone has filed an IND in the US with Rabeximod following positive feed-back from pre-IND meeting with the FDA

    December 15, 2020 09:26 (CET)
    Regulatory
    MAR

    Cyxone (publ.), a clinical stage biotech company developing first-in-class drugs for diseases of the immune system, announced today that the company has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) pertaining to its drug candidate Rabeximod. The application follows on a productive pre-IND meeting with the authority, where valuable advice was received on inter alia the protocol for its imminent European Phase 2 clinical study in moderate Covid-19. The IND covers the development of Rabeximod in Covid-19 and other indications, such as rheumatoid arthritis, and is a prerequisite for a future validation of the company’s five recent patent applications in the US market.

    Read more

  • Cyxone has decided to apply for a listing of its share on Nasdaq Stockholm Main Market

    December 9, 2020 08:26 (CET)
    Regulatory

    Cyxone (publ.) announced today that its Board of Directors has decided to apply for a listing of the company’s share on Nasdaq Stockholm Main Market. The company will prepare to submit an application in the first quarter of 2022. Cyxone is currently listed on Nasdaq First North Growth Market.

    Read more

  • Cyxone receives regulatory approval to initiate a clinical Phase 2 study with Rabeximod in Covid-19 patients

    December 8, 2020 14:46 (CET)
    Regulatory

    Cyxone (publ.) announced today it has received approval from the regulatory authority and the ethics committee in Poland to initiate a Phase 2 clinical trial with Rabeximod in moderate Covid-19 patients. The oral treatment is intended to prevent the progression to acute respiratory distress symptoms (ARDS) caused by virus-related overactivation of the immune system. Preliminary results are expected in the third quarter of 2021.

    Read more

  • First day of trading with warrants of series TO4

    November 27, 2020 14:51 (CET)
    Regulatory

    As previously communicated, Cyxone AB (publ) (“Cyxone” or the “Company”) has resolved to allocate one (1) warrant of series TO4 to the Company’s existing shareholders for every twenty-eight (28) shares owned on the record date of November 19, 2020. The Warrants will, to some extent, compensate the current shareholders in the Company for the dilution that the previously conducted directed issue of shares and warrants entails. In this context, the Company simultaneously announces that the first day for trading with warrants of series TO4 on Nasdaq First North Growth Market has been set to November 30, 2020.

    Read more

  • Record date for the distribution of warrants of series TO4 to current shareholders is set to November 19, 2020

    November 16, 2020 14:59 (CET)
    Regulatory

    On November 10 2020, the board of directors of Cyxone AB (publ), (“Cyxone” or the “Company”) decided to carry out a Directed Issue (the “Directed Issue”), and to issue warrants of series TO4 to the current shareholders of Cyxone who on the record date holds shares in the Company. The warrants will, to some extent, compensate the current shareholders in the Company for the dilution in the Directed Issue.

    Read more